Tumor mutational burden and purity adjustment before and after treatment with temozolomide in 27 paired samples of glioblastoma: a prospective study

Treatment of glioblastoma (GBM) remains a challenging task, with limited treatment options, none offering a cure. Immune therapy has proven effective across different cancers with remarkable response rates. Tumor mutational burden (TMB) is a marker of response, but technical and methodological diffe...

Descripción completa

Detalles Bibliográficos
Autores principales: Schou Nørøxe, Dorte, Flynn, Aidan, Westmose Yde, Christina, Østrup, Olga, Cilius Nielsen, Finn, Skjøth‐Rasmussen, Jane, Brennum, Jannick, Hamerlik, Petra, Weischenfeldt, Joachim, Skovgaard Poulsen, Hans, Lassen, Ulrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732341/
https://www.ncbi.nlm.nih.gov/pubmed/34018316
http://dx.doi.org/10.1002/1878-0261.13015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8732341/
https://www.ncbi.nlm.nih.gov/pubmed/34018316
http://dx.doi.org/10.1002/1878-0261.13015

Ejemplares similares